FTO-话题@MedSci

#FTO#

23篇内容 | 1830人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2192541, encodeId=2c57219254118, content=<a href='/topic/show?id=bb09e67752b' target=_blank style='color:#2F92EE;'>#糖尿病视网膜病变#</a> <a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a> <a href='/topic/show?id=9f066230d6' target=_blank style='color:#2F92EE;'>#DR#</a>, objectTitle=EMM：南京医科大学刘庆淮/陈雪发现乳酸化驱动的FTO靶向CDK2加重糖尿病视网膜病变微血管异常, objectType=article, longId=816592, objectId=d4518165925e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301012/1697149686458_4754896.jpeg, objectUrl=/article/show_article.do?id=d4518165925e, replyNumber=0, likeNumber=77, createdTime=2024-03-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d4518165925e, moduleTitle=EMM：南京医科大学刘庆淮/陈雪发现乳酸化驱动的FTO靶向CDK2加重糖尿病视网膜病变微血管异常, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4518165925e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1478176, encodeId=738f14e81768e, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, objectType=article, longId=207122, objectId=8d1120e122ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d1120e122ef, replyNumber=0, likeNumber=84, createdTime=2021-02-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d1120e122ef, moduleTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d1120e122ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, objectType=article, longId=203872, objectId=e95e2038e2f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95e2038e2f3, replyNumber=0, likeNumber=74, createdTime=2020-12-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95e2038e2f3, moduleTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e95e2038e2f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478174, encodeId=b0d114e81749d, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, objectType=article, longId=201255, objectId=b45e20125596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45e20125596, replyNumber=0, likeNumber=76, createdTime=2020-09-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45e20125596, moduleTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45e20125596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478173, encodeId=449114e817314, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, objectType=article, longId=195394, objectId=51fd195394e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51fd195394e1, replyNumber=0, likeNumber=74, createdTime=2020-06-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51fd195394e1, moduleTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51fd195394e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478172, encodeId=0c3214e8172b7, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, objectType=article, longId=191946, objectId=1e43191946c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e43191946c0, replyNumber=0, likeNumber=91, createdTime=2020-04-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e43191946c0, moduleTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e43191946c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478171, encodeId=97b214e817199, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=NEJM：Elexacaftor-Tezacaftor-Ivacaftor治疗PHE508DEL型囊性纤维化, objectType=article, longId=182254, objectId=767318225483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=767318225483, replyNumber=0, likeNumber=96, createdTime=2019-11-03, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=767318225483, moduleTitle=NEJM：Elexacaftor-Tezacaftor-Ivacaftor治疗PHE508DEL型囊性纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=767318225483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478170, encodeId=3bd914e817022, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=欧洲CHMP持正面意见：KALYDECO（ivacaftor）治疗囊性纤维化婴儿, objectType=article, longId=181644, objectId=9c2d1816444b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d1816444b, replyNumber=0, likeNumber=118, createdTime=2019-10-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d1816444b, moduleTitle=欧洲CHMP持正面意见：KALYDECO（ivacaftor）治疗囊性纤维化婴儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2d1816444b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478169, encodeId=ce9e14e816990, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, objectType=article, longId=166645, objectId=66b1166645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66b1166645d2, replyNumber=0, likeNumber=109, createdTime=2019-05-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66b1166645d2, moduleTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66b1166645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478168, encodeId=b45814e816881, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Sci Transl Med：揭示肥胖相关基因FTO调控能量代谢新机制, objectType=article, longId=164815, objectId=e74716481599, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e74716481599, replyNumber=0, likeNumber=83, createdTime=2019-04-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e74716481599, moduleTitle=Sci Transl Med：揭示肥胖相关基因FTO调控能量代谢新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e74716481599)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478167, encodeId=ad5814e81675a, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Cancer Cell：FTO抑制剂研究新进展, objectType=article, longId=164535, objectId=db25164535d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db25164535d7, replyNumber=0, likeNumber=110, createdTime=2019-04-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db25164535d7, moduleTitle=Cancer Cell：FTO抑制剂研究新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db25164535d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478166, encodeId=8af714e8166f3, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=加拿大卫生部授予KALYDECO（ivacaftor）治疗12个月至24个月囊性纤维化儿童的市场授权, objectType=article, longId=159164, objectId=c6ec15916468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6ec15916468, replyNumber=0, likeNumber=106, createdTime=2019-01-31, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6ec15916468, moduleTitle=加拿大卫生部授予KALYDECO（ivacaftor）治疗12个月至24个月囊性纤维化儿童的市场授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6ec15916468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478165, encodeId=f1b014e8165ed, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=加拿大卫生部批准ORKAMBI（lumacaftor / ivacaftor）治疗儿童囊性纤维化, objectType=article, longId=155810, objectId=8a0115581040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a0115581040, replyNumber=0, likeNumber=95, createdTime=2018-12-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a0115581040, moduleTitle=加拿大卫生部批准ORKAMBI（lumacaftor / ivacaftor）治疗儿童囊性纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a0115581040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478164, encodeId=835c14e816411, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=NEJM：VX-445-Tezacaftor-Ivacaftor用于治疗Phe508del突变型囊性纤维化, objectType=article, longId=151875, objectId=578e1518e5bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=578e1518e5bf, replyNumber=0, likeNumber=76, createdTime=2018-10-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=578e1518e5bf, moduleTitle=NEJM：VX-445-Tezacaftor-Ivacaftor用于治疗Phe508del突变型囊性纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=578e1518e5bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478163, encodeId=c8de14e816345, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化, objectType=article, longId=151869, objectId=2ac215186978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ac215186978, replyNumber=0, likeNumber=126, createdTime=2018-10-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ac215186978, moduleTitle=NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ac215186978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478162, encodeId=e18914e81629a, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, objectType=article, longId=149597, objectId=26f714959eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26f714959eaf, replyNumber=0, likeNumber=54, createdTime=2018-09-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26f714959eaf, moduleTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f714959eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478161, encodeId=cfb014e8161b1, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=欧洲CHMP对SYMKEVI（tezacaftor / ivacaftor）持积极态度, objectType=article, longId=145412, objectId=a2591454128b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2591454128b, replyNumber=0, likeNumber=110, createdTime=2018-07-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2591454128b, moduleTitle=欧洲CHMP对SYMKEVI（tezacaftor / ivacaftor）持积极态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2591454128b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478160, encodeId=efd714e8160e9, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, objectType=article, longId=141927, objectId=83be14192e7c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83be14192e7c, replyNumber=0, likeNumber=121, createdTime=2018-06-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83be14192e7c, moduleTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83be14192e7c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478159, encodeId=01b614e815929, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, objectType=article, longId=101423, objectId=a07f101423fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a07f101423fa, replyNumber=0, likeNumber=142, createdTime=2017-06-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a07f101423fa, moduleTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a07f101423fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478158, encodeId=a45314e8158ef, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, objectTitle=Cancer Cell：重审FTO在白血病中的癌基因作用, objectType=article, longId=98783, objectId=659d98e8397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659d98e8397, replyNumber=0, likeNumber=84, createdTime=2017-05-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659d98e8397, moduleTitle=Cancer Cell：重审FTO在白血病中的癌基因作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=659d98e8397)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FTO

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病视网膜病变# #FTO# #DR#

EMM：南京医科大学刘庆淮/陈雪发现乳酸化驱动的FTO靶向CDK2加重糖尿病视网膜病变微血管异常

2024-03-11发表于上海

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后

2021-02-16

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

NICE支持Braftovi治疗BRAF阳性转移性结直肠癌

2020-12-01

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿

2020-09-28

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌

2020-06-07

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌

2020-04-11

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

NEJM：Elexacaftor-Tezacaftor-Ivacaftor治疗PHE508DEL型囊性纤维化

2019-11-03

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

欧洲CHMP持正面意见：KALYDECO（ivacaftor）治疗囊性纤维化婴儿

2019-10-22

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率

2019-05-24

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Sci Transl Med：揭示肥胖相关基因FTO调控能量代谢新机制

2019-04-24

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Cancer Cell：FTO抑制剂研究新进展

2019-04-20

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

加拿大卫生部授予KALYDECO（ivacaftor）治疗12个月至24个月囊性纤维化儿童的市场授权

2019-01-31

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

加拿大卫生部批准ORKAMBI（lumacaftor / ivacaftor）治疗儿童囊性纤维化

2018-12-16

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

NEJM：VX-445-Tezacaftor-Ivacaftor用于治疗Phe508del突变型囊性纤维化

2018-10-27

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化

2018-10-27

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤

2018-09-27

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

欧洲CHMP对SYMKEVI（tezacaftor / ivacaftor）持积极态度

2018-07-30

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤

2018-06-30

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？

2017-06-11

仁者大医 (审核中...)

前往app查看评论内容

#FTO#

Cancer Cell：重审FTO在白血病中的癌基因作用

2017-05-17

科室
- - 订阅+
  - 更多科室
工具
服务